デフォルト表紙
市場調査レポート
商品コード
1563093

ミトタン市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年

Mitotane Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 206 Pages
納期
2～5営業日
カスタマイズ可能
ミトタン市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年
出版日: 2024年09月25日
発行: Persistence Market Research
ページ情報: 英文 206 Pages
納期: 2～5営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界のミトタン市場に関する包括的なレポートを発行し、市場促進要因・動向・機会・課題などの主要な市場力学を分析しています。本レポートは、市場構造に関する深い洞察と今後10年間の成長予測を提供しています。

主要な洞察

  • ミトタンの市場規模（2024年）：610万米ドル
  • 予測市場規模（2033年）：2,410万米ドル
  • 世界市場成長率（CAGR 2024～2033年）：4.6%

ミトタン市場：調査範囲

ミトタン市場は、主に副腎を侵す希少がんである副腎皮質がん（ACC）の治療に使用されるこの化学療法薬の世界需要を網羅しています。ミトタンは、副腎皮質で産生されるホルモンの産生を阻害する能力で知られ、腫瘍を効果的に縮小させたり、成長を遅らせたりします。ミトタンは、腫瘍学において併用療法の一部として利用されることが多いです。

ミトタンの市場は、ACCの罹患率の増加、がん治療プロトコルの進歩、希少がんセグメントの進行中の研究により、着実に成長しています。さらに、ドラッグデリバリー機構の改善、医療インフラの拡大、ACC治療の選択肢に対する意識の高まりが需要を牽引しています。

市場促進要因：

いくつかの重要な要因が世界のミトタン市場の成長を促進しています。まず、副腎皮質がんの有病率の増加が重要な促進要因であり、毎年診断される症例数が増加しています。早期発見と高度な診断技術に対する意識の高まりがACCの同定を改善し、ミトタンの需要をさらに押し上げています。

第二に、ミトタンの有効性を高め、副作用を軽減することに焦点を当てた研究開発の進行が、市場拡大に寄与しています。研究者は、治療成績を改善するためにミトタンと他の化学療法剤を統合する併用療法を模索しています。

さらに、特に発展途上地域における医療施設や腫瘍センターの拡大が、ミトタンの治療へのアクセスを促進しています。医療のインフラが改善し続けるにつれて、専門的ながん治療が受けられるようになり、より多くの患者がこの救命薬を利用できるようになっています。

最後に、患者の意識向上キャンペーンと希少がん擁護団体の支援は、治療の選択肢を増やす上で重要な役割を果たしており、最終的にミトタン市場に利益をもたらしています。

市場抑制要因：

有望な成長展望にもかかわらず、ミトタン市場は課題に直面しています。主要制約は、ミトタン療法に関連する高額な費用であり、特に中低所得国での購入が制限される可能性があります。さらに、胃腸障害、神経学的影響、コルチゾールレベルへの影響など、ミトタンの副作用は患者のコンプライアンス低下を招き、市場成長に影響を及ぼす可能性があります。

もう1つの課題は、サプライチェーンの制約やこの希少がん治療の市場規模が小さいため、特定の地域ではミトタンの入手が限られていることです。医薬品承認に関連する規制上のハードルや、新製剤の上市までの長いタイムラインも、市場参入企業にとって課題となっています。

さらに、副腎皮質がん治療の訓練を受けた専門医療従事者の不足が、特に新興国における市場の成長をさらに制限しています。

市場機会：

ミトタン市場は、特に個別化医療と標的療法への注目が高まる中で、大きな成長機会を示しています。分子診断学の調査により、患者の層別化が進み、個々の遺伝子プロファイルに基づいたより正確なミトタン治療が可能になりつつあります。これにより、治療成績が向上するだけでなく、副作用が最小限に抑えられ、患者のアドヒアランスが向上します。

さらに、製薬企業と研究機関とのパートナーシップは、新しいミトタンの製剤開発における技術革新に拍車をかけることが期待されます。これらの提携は、薬効を高め、新規ドラッグデリバリーシステムを探求し、毒性を低減することを目的としており、市場拡大の新たな道を開くものです。

遠隔医療やデジタルヘルスプラットフォームの受け入れが拡大していることも、機会のあるセグメントです。これらの技術は、特に専門医療施設へのアクセスが限られている地域において、ミトタン治療中の患者モニタリングやフォローアップ治療をより効果的に行うことを可能にします。

さらに、新興市場における医療予算の拡大やがん治療の改善を目的とした政府の取り組みにより、ミトタンの利用しやすさが向上し、今後数年間の市場拡大が期待されます。

本レポートで扱う主要質問

  • 世界のミトタン市場の成長を促進する主要要因は何か？
  • 技術の進歩はミトタン市場の競合情勢にどのような影響を与えているか？
  • ミトタン治療に関連する課題は何か、またどのように対処しているか？
  • ミトタン市場で最も高い成長が見込まれる地域は？
  • ミトタン市場の主要参入企業は誰か、競合を維持するためにどのような戦略を採用しているか？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主要動向
  • イノベーション/開発動向

第4章 付加価値の洞察

  • 疾病疫学
  • パイプライン評価
  • 患者の治療の過程
  • 規制状況
  • 償還シナリオ
  • PESTEL分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因-関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 適応症別
    • 流通チャネル別
    • 国別
  • 2023年の市場シナリオ

第7章 世界市場の需要（金額または規模、100万米ドル）分析

  • 過去の市場金額（100万米ドル）分析、2019～2023年
  • 現在と将来の市場金額（100万米ドル）予測、2024～2033年
    • 前年比成長動向分析
    • 絶対的収益機会

第8章 症状別の世界の市場分析

  • イントロダクション/主要調査結果
  • 過去の市場規模（100万米ドル）分析、症状別、2019～2023年
  • 現在と将来の市場規模（100万米ドル）の分析と予測、症状別、2024～2033年
    • クッシング病（CD）
    • 副腎皮質がん（ACC）
  • 症状別市場の魅力分析

第9章 流通チャネル別の世界の市場分析

  • イントロダクション/主要調査結果
  • 過去の市場規模（100万米ドル）分析、流通チャネル別、2019～2023年
  • 現在と将来の市場規模（100万米ドル）の分析と予測、流通チャネル別、2024～2033年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • 専門クリニック
  • 流通チャネル別市場の魅力分析

第10章 地域別の世界の市場分析

  • イントロダクション
  • 地域別市場規模（100万米ドル）の過去分析、2019～2023年
  • 現在と将来の市場金額（100万米ドル）の分析と予測、地域別2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別市場の魅力分析

第11章 北米の分析

第12章 ラテンアメリカの分析

第13章 欧州の分析

第14章 東アジアの分析

第15章 南アジアの分析

第16章 オセアニアの分析

第17章 中東・アフリカの分析

第18章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第19章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • HRA Pharma Rare Diseases
    • Bristol-Myers Squibb Company

第20章 使用される仮定と頭字語

第21章 調査手法

目次
Product Code: PMRREP30052

Persistence Market Research has recently published a comprehensive report on the global Mitotane Market, analyzing key market dynamics, including drivers, trends, opportunities, and challenges. This report offers in-depth insights into the market structure and growth projections for the coming decade.

Key Insights:

  • Mitotane Market Size (2024E): US$6.1 Mn
  • Projected Market Value (2033F): US$24.1 Mn
  • Global Market Growth Rate (CAGR 2024 to 2033): 4.6%

Mitotane Market - Report Scope:

The Mitotane Market encompasses the global demand for this chemotherapy drug, primarily used to treat adrenocortical carcinoma (ACC), a rare cancer that affects the adrenal glands. Mitotane is known for its ability to inhibit the production of hormones produced by the adrenal cortex, effectively shrinking tumors or slowing their growth. It is often utilized as part of combination therapies in oncology.

The market for Mitotane is growing steadily due to the increasing incidence of ACC, advancements in cancer treatment protocols, and ongoing research in the field of rare cancers. Additionally, improvements in drug delivery mechanisms, expanding healthcare infrastructure, and the growing awareness of ACC treatment options are driving demand.

Market Growth Drivers:

Several key factors are propelling the growth of the global Mitotane Market. Firstly, the increasing prevalence of adrenocortical carcinoma is a significant driver, with a growing number of cases being diagnosed each year. The rising awareness of early detection and advanced diagnostic techniques is improving the identification of ACC, further boosting Mitotane demand.

Secondly, ongoing research and development efforts focused on enhancing Mitotane's efficacy and reducing side effects are contributing to market expansion. Researchers are exploring combination therapies that integrate Mitotane with other chemotherapy agents to improve treatment outcomes.

Furthermore, the expansion of healthcare facilities and oncology centers, particularly in developing regions, is driving the accessibility of Mitotane treatments. As healthcare infrastructure continues to improve, the availability of specialized cancer treatment is increasing, providing more patients with access to this life-saving drug.

Lastly, patient awareness campaigns and the support of advocacy groups for rare cancers are playing a vital role in enhancing treatment options, ultimately benefiting the Mitotane market.

Market Restraints:

Despite promising growth prospects, the Mitotane Market faces challenges. The primary limitation is the high cost associated with Mitotane therapy, which can restrict its affordability, particularly in low- and middle-income countries. Additionally, the side effects of Mitotane, such as gastrointestinal issues, neurological effects, and its impact on cortisol levels, can lead to poor patient compliance, thereby affecting market growth.

Another challenge is the limited availability of Mitotane in certain regions due to supply chain constraints and the small market size for this rare cancer treatment. Regulatory hurdles related to drug approvals and the long timeline for bringing new formulations to market also pose challenges for market players.

Moreover, the lack of specialized healthcare professionals trained in handling adrenocortical carcinoma treatment further restricts market growth, particularly in emerging economies.

Market Opportunities:

The Mitotane Market presents significant opportunities for growth, especially with the increasing focus on personalized medicine and targeted therapies. Research in molecular diagnostics is paving the way for better patient stratification, allowing for more precise treatment with Mitotane based on individual genetic profiles. This not only improves treatment outcomes but also minimizes side effects, driving patient adherence.

Additionally, partnerships between pharmaceutical companies and research institutions are expected to spur innovation in the development of new Mitotane formulations. These collaborations aim to enhance drug efficacy, explore novel drug delivery systems, and reduce toxicity, opening new avenues for market expansion.

The growing acceptance of telemedicine and digital health platforms is another area of opportunity. These technologies allow for more effective patient monitoring and follow-up care during Mitotane treatment, especially in regions with limited access to specialized healthcare facilities.

Furthermore, expanding healthcare budgets and government initiatives aimed at improving cancer care in emerging markets are expected to increase the accessibility of Mitotane, thereby boosting the market in the coming years.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global Mitotane Market?
  • How are technological advancements influencing the competitive landscape of the Mitotane Market?
  • What are the challenges associated with Mitotane therapy, and how are they being addressed?
  • Which regions are expected to show the highest growth in the Mitotane Market?
  • Who are the key players in the Mitotane Market, and what strategies are they employing to maintain competitiveness?

Competitive Intelligence and Business Strategy:

The global Mitotane Market is characterized by the presence of several key players who are investing heavily in research and development to improve treatment outcomes and reduce side effects. Companies are also focusing on expanding their distribution networks and forming strategic partnerships with healthcare providers and research institutions to strengthen their market presence.

Leading players, such as HRA Pharma, Bristol-Myers Squibb, and Teva Pharmaceutical Industries, are at the forefront of innovation in the Mitotane market. These companies are also focusing on market expansion strategies, such as mergers and acquisitions, to enhance their product portfolios and increase market share.

In addition to product innovation, these companies are engaging in awareness campaigns aimed at educating patients and healthcare professionals about the benefits and proper administration of Mitotane. By increasing the understanding of this chemotherapy drug, they aim to drive market growth and expand their customer base.

Key Companies Profiled:

  • HRA Pharma Rare Diseases
  • Bristol-Myers Squibb Company

Mitotane Market Industry Segmentation

Indication:

  • Cushing's Disease (CD)
  • Adrenocortical carcinoma

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Value Added Insights

  • 4.1. Disease Epidemiology
  • 4.2. Pipeline Assessment
  • 4.3. Patient Treatment Journey
  • 4.4. Regulatory Landscape
  • 4.5. Reimbursement Scenario
  • 4.6. PESTEL Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Adrenocortical Carcinoma Treatment Market Overview
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increasing Number of Carcinoma Treatment
    • 5.2.2. Growing Incidence of Adrenal Cancer Cases
    • 5.2.3. Rising Incidence of Cushing's Syndrome
    • 5.2.4. Cost of Treatment
    • 5.2.5. Treatment Adoption Rate
    • 5.2.6. Players Penetration into Emerging Markets
    • 5.2.7. Strategic Collaborations Among Players
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Indication
    • 6.1.2. By Distribution Channel
    • 6.1.3. By Country
  • 6.2. 2023 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2033
    • 8.3.1. Cushing's Disease (CD)
    • 8.3.2. Adrenocortical carcinoma (ACC)
  • 8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Specialty Clinics
  • 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Region 2024-2033
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (Middle East and Africa)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Analysis 2019-2023 and Forecast 2024-2033

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Market Taxonomy 2024-2033
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Indication
    • 11.3.3. By Distribution Channel
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Indication
    • 11.4.3. By Distribution Channel
  • 11.5. Market Trends
  • 11.6. Drivers and Restraints - Impact Analysis
  • 11.7. Key Players - Intensity Mapping
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Analysis
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Indication
        • 11.8.1.2.2. By Distribution Channel
    • 11.8.2. Canada Analysis
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Indication
        • 11.8.2.2.2. By Distribution Channel
        • 11.8.2.2.3. By Distribution Channel

12. Latin America Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Market Taxonomy 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Indication
    • 12.3.3. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Indication
    • 12.4.3. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Indication
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Brazil Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Indication
        • 12.8.2.2.2. By Distribution Channel
    • 12.8.3. Argentina Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Indication
        • 12.8.3.2.2. By Distribution Channel

13. Europe Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Market Taxonomy 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Indication
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Indication
    • 13.4.3. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Indication
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Italy Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Indication
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. France Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Indication
        • 13.8.3.2.2. By Distribution Channel
    • 13.8.4. U.K. Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Indication
        • 13.8.4.2.2. By Distribution Channel
    • 13.8.5. Spain Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Indication
        • 13.8.5.2.2. By Distribution Channel
    • 13.8.6. BENELUX Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Indication
        • 13.8.6.2.2. By Distribution Channel
    • 13.8.7. Russia Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Indication
        • 13.8.7.2.2. By Distribution Channel

14. East Asia Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Market Taxonomy 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Indication
    • 14.3.3. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Indication
    • 14.4.3. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Indication
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. Japan Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Indication
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. South Korea Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Indication
        • 14.8.3.2.2. By Distribution Channel

15. South Asia Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Market Taxonomy 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Indication
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Indication
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Indication
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Indonesia Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Indication
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. Malaysia Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Indication
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Thailand Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Indication
        • 15.8.4.2.2. By Distribution Channel

16. Oceania Market 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Market Taxonomy 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Indication
    • 16.3.3. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Indication
    • 16.4.3. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Indication
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. New Zealand Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Indication
        • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (Middle East and Africa) Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Market Taxonomy 2024-2033
    • 17.3.1.By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkiye
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Indication
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Indication
    • 17.4.3. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Indication
        • 17.8.1.2.2. By Distribution Channel
    • 17.8.2. Turkiye Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Indication
        • 17.8.2.2.2. By Distribution Channel
    • 17.8.3. South Africa Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Indication
        • 17.8.3.2.2. By Distribution Channel
    • 17.8.4. North Africa Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Indication
        • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Benchmarking
  • 19.3. Competition Deep Dive
    • 19.3.1. HRA Pharma Rare Diseases
      • 19.3.1.1. Overview
      • 19.3.1.2. Indication Portfolio
      • 19.3.1.3. Sales Footprint
      • 19.3.1.4. Key Financials
      • 19.3.1.5. SWOT Analysis
      • 19.3.1.6. Strategy Overview
    • 19.3.2. Bristol-Myers Squibb Company
      • 19.3.2.1. Overview
      • 19.3.2.2. Indication Portfolio
      • 19.3.2.3. Sales Footprint
      • 19.3.2.4. Key Financials
      • 19.3.2.5. SWOT Analysis
      • 19.3.2.6. Strategy Overview

20. Assumptions and Acronyms Used

21. Research Methodology